Viewing Study NCT02130505


Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2026-02-23 @ 8:07 PM
Study NCT ID: NCT02130505
Status: COMPLETED
Last Update Posted: 2014-05-05
First Post: 2014-04-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
Sponsor: Sint Franciscus Gasthuis
Organization:

Study Overview

Official Title: Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
Status: COMPLETED
Status Verified Date: 2014-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: INFORM
Brief Summary: In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.
Detailed Description: Cardiovascular disease (CVD) is number one killer in the Netherlands. Insulin resistance and dyslipideima are the main causes of CVD. Recently, we have shown that there is an acute leukocyte activation after an oral glucose tolerance test (OGTT) in patients with newly-diagnosed diabets mellitus type 2 (T2DM). Leukocyte activation is an important and obligatory aspect in the process of atherosclerosis. Complement system is another important inflammatory component in atherosclerosis, which becomes activated in the postprandial phase.

In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: